Skip to main content
SpringerLink
Log in

Efficacy and Safety of 308-nm Monochromatic Excimer Lamp Versus Other Phototherapy Devices for Vitiligo: A Systematic Review with Meta-Analysis

  • Evidence-Based Review
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Background

Various phototherapy methods are used to treat vitiligo; however, the recent emergence of new devices has heightened debate concerning the best treatment method.

Objective

We aimed to systematically review and meta-analyze published data comparing the efficacy and adverse effects of monochromatic excimer lamps versus excimer laser and narrowband ultraviolet B (NB-UVB) in treating vitiligo.

Methods

A systematic search of PubMed, EMBASE, LILACS, Cochrane Central Register of Controlled Trials (CENTRAL), and clinical trials registries identified randomized controlled trials that included vitiligo patients, regardless of age, sex, or study language. We evaluated studies comparing excimer lamps with excimer laser or NB-UVB phototherapy.

Results

The review included six studies (411 patients, 764 lesions). No study found significantly different efficacy between excimer lamps and excimer laser using the outcomes of ≥50 % repigmentation [risk ratio (RR) = 0.97, 95 % confidence interval (CI) 0.84–1.11] and ≥75 % repigmentation (RR = 0.96, 95 % CI 0.71–1.30). Likewise, no study found significant differences between excimer lamps and NB-UVB (RR = 1.14, 95 % CI 0.88–1.48 for ≥50 % repigmentation; RR = 1.81, 95 % CI 0.11–29.52 for ≥75 % repigmentation). Adverse effects were mild, including pruritus, burning sensation, and dryness, none of which interrupted treatment.

Conclusions

To our knowledge, this is the first systematic review of the efficacy and safety of excimer lamp treatment for vitiligo. Excimer lamps, excimer laser, and NB-UVB are all safe and effective in repigmentation of vitiligo lesions. Safety, effectiveness, and cost are considerations when choosing treatment.

PROSPERO Registration Number

CRD42014015237.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Lotti T, D’Erme AM. Vitiligo as a systemic disease. Clin Dermatol. 2014;32:430–4.

    Article  PubMed  Google Scholar 

  2. Ding GZ, Zhao WE, Li X, Gong QL, Lu Y. A comparative study of mitochondrial ultrastructure in melanocytes from perilesional vitiligo skin and perilesional halo nevi skin. Arch Dermatol Res. 2015;307:281–9.

    Article  PubMed  CAS  Google Scholar 

  3. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a review of the published work. J Dermatol. 2011;38:419–31.

    Article  PubMed  Google Scholar 

  4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74–84.

    Article  PubMed  Google Scholar 

  5. Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168:5–19.

    Article  PubMed  CAS  Google Scholar 

  6. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65:473–91.

    Article  PubMed  Google Scholar 

  7. Teovska Mitrevska N, Eleftheriadou V, Guarneri F. Quality of life in vitiligo patients. Dermatol Ther. 2012;25:S28–31.

  8. Sampogna F. Life course impairment and quality of life over time. Curr Probl Dermatol. 2013;44:47–51.

    Article  PubMed  Google Scholar 

  9. Mishra N, Rastogi MK, Gahalaut P, Agrawal S. Dermatology specific quality of life in vitiligo patients and its relation with various variables: a hospital based cross-sectional study. J Clin Diagn Res. 2014;8:YC01–3.

  10. Krüger C, Schallreuter KU. Stigmatisation, avoidance behaviour and difficulties in coping are common among adult patients with vitiligo. Acta Derm Venereol. 2015;95:553–8.

    Article  PubMed  Google Scholar 

  11. Ezzedine K, Grimes PE, Meurant JM, Seneschal J, Léauté-Labrèze C, Ballanger F, et al. Living with vitiligo: results from a national survey indicate differences between skin phototypes. Br J Dermatol. 2015;173:607–9.

    Article  PubMed  CAS  Google Scholar 

  12. Bin Saif GA, Al-Balbeesi AO, Binshabaib R, Alsaad D, Kwatra SG, Alzolibani AA, et al. Quality of life in family members of vitiligo patients: a questionnaire study in Saudi Arabia. Am J Clin Dermatol. 2013;14:489–95.

    Article  PubMed  Google Scholar 

  13. Malhotra N, Dytoc M. The pathogenesis of vitiligo. J Cutan Med Surg. 2013;17:153–72.

    Article  PubMed  CAS  Google Scholar 

  14. Czajkowski R, Męcińska-Jundziłł K. Current aspects of vitiligo genetics. Postepy Dermatol Alergol. 2014;31:247–55.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Spritz RA. Modern vitiligo genetics sheds new light on an ancient disease. J Dermatol. 2013;40:310–8.

    Article  PubMed  CAS  Google Scholar 

  16. Ghafourian A, Ghafourian S, Sadeghifard N, Mohebi R, Shokoohini Y, Nezamoleslami S, et al. Vitiligo: symptoms, pathogenesis and treatment. Int J Immunopathol Pharmacol. 2014;27:485–9.

    PubMed  CAS  Google Scholar 

  17. Speeckaert R, Speeckaert MM, van Geel N. Why treatments do(n’t) work in vitiligo: an autoinflammatory perspective. Autoimmun Rev. 2015;14:332–40.

    Article  PubMed  CAS  Google Scholar 

  18. Lin X, Tang LY, Fu WW, Kang KF. Childhood vitiligo in China: clinical profiles and immunological findings in 620 cases. Am J Clin Dermatol. 2011;12:277–81.

    Article  PubMed  Google Scholar 

  19. Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, Yeola AP, et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol. 2014;23:352–3.

    Article  PubMed  CAS  Google Scholar 

  20. Zedan H, Abdel-Motaleb AA, Kassem NM, Hafeez HA, Hussein MR. Low glutathione peroxidase activity levels in patients with vitiligo. J Cutan Med Surg. 2015;19:144–8.

    PubMed  Google Scholar 

  21. Güntaş G, Engin B, Ekmekçi ÖB, Kutlubay Z, Ekmekci H, Songür A, et al. Evaluation of advanced oxidation protein products, prooxidant-antioxidant balance, and total antioxidant capacity in untreated vitiligo patients. Ann Dermatol. 2015;27:178–83.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Camara-Lemarroy CR, Salas-Alanis JC. The role of tumor necrosis factor-α in the pathogenesis of vitiligo. Am J Clin Dermatol. 2013;14:343–50.

    Article  PubMed  Google Scholar 

  23. Kumar R, Parsad D, Kanwar AJ. Role of apoptosis and melanocytorrhagy: a comparative study of melanocyte adhesion in stable and unstable vitiligo. Br J Dermatol. 2011;164:187–91.

    Article  PubMed  CAS  Google Scholar 

  24. Kumar R, Parsad D. Melanocytorrhagy and apoptosis in vitiligo: connecting jigsaw pieces. Indian J Dermatol Venereol Leprol. 2012;78:19–23.

    Article  PubMed  Google Scholar 

  25. Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013;17:259–68.

    Article  PubMed  CAS  Google Scholar 

  26. Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015;2:CD003263. doi:10.1002/14651858.CD003263.pub5.

  27. Du J, Wang XY, Ding XL, Xu QX, Chen Z, Chang JM, et al. Long-term efficacy and safety of tacrolimus ointment in the treatment of vitiligo. J Dermatol. 2013;40:935–6.

    Article  PubMed  CAS  Google Scholar 

  28. Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, et al. Maintenance therapy of adult vitiligo with 0.1 % tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135:970–4.

    Article  PubMed  Google Scholar 

  29. Newman MD, Silverberg NB. Once-daily application of calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for repigmentation of facial vitiligo. Cutis. 2011;88:256–9.

    PubMed  Google Scholar 

  30. Hossani-Madani A, Halder R. Treatment of vitiligo: advantages and disadvantages, indications for use and outcomes. G Ital Dermatol Venereol. 2011;146:373–95.

    PubMed  CAS  Google Scholar 

  31. Wong R, Lin AN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol. 2013;52:491–6.

    Article  PubMed  CAS  Google Scholar 

  32. Lim HW, Grimes PE, Lebwohl M. Indications and limitations of afamelanotide for treating vitiligo-reply. JAMA Dermatol. 2015;151:350.

    Article  PubMed  Google Scholar 

  33. Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42–50.

    Article  PubMed  Google Scholar 

  34. Singh C, Parsad D, Kanwar AJ, Dogra S, Kumar R. Comparison between autologous noncultured extracted hair follicle outer root sheath cell suspension and autologous noncultured epidermal cell suspension in the treatment of stable vitiligo: a randomized study. Br J Dermatol. 2013;169:287–93.

    Article  PubMed  CAS  Google Scholar 

  35. Bacigalupi RM, Postolova A, Davis RS. Evidence-based, non-surgical treatments for vitiligo: a review. Am J Clin Dermatol. 2012;13:217–37.

    Article  PubMed  Google Scholar 

  36. Machado Filho CD. Timoner FR. Epidermal curettage technique (ECT) for tissue harvest from the donor area for melanocyte autologous grafting in cases of vitiligo. An Bras Dermatol. 2014;89:681–3.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Sapam R, Agrawal S, Dhali TK. Systemic PUVA vs. narrowband UVB in the treatment of vitiligo: a randomized controlled study. Int J Dermatol. 2012;51:1107–15.

    Article  PubMed  Google Scholar 

  38. Akar A, Tunca M, Koc E, Kurumlu Z. Broadband targeted UVB phototherapy for localized vitiligo: a retrospective study. Photodermatol Photoimmunol Photomed. 2009;25:161–3.

    Article  PubMed  Google Scholar 

  39. Yazdani Abyaneh M, Griffith RD, Falto-Aizpurua L, Nouri K. Narrowband ultraviolet B phototherapy in combination with other therapies for vitiligo: mechanisms and efficacies. J Eur Acad Dermatol Venereol. 2014;28:1610–22.

  40. Hallaji Z, Ghiasi M, Eisazadeh A, Damavandi MR. Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed. 2012;28:115–9.

    Article  PubMed  Google Scholar 

  41. Akdeniz N, Yavuz IH, Gunes Bilgili S, Ozaydın Yavuz G, Calka O. Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasone and calcipotriol in vitiligo. J Dermatolog Treat. 2014;25:196–9.

    Article  PubMed  CAS  Google Scholar 

  42. Alhowaish AK, Dietrich N, Onder M, Fritz K. Effectiveness of a 308-nm excimer laser in treatment of vitiligo: a review. Lasers Med Sci. 2013;28:1035–41.

    Article  PubMed  Google Scholar 

  43. Park KK, Liao W, Murase JE. A review of monochromatic excimer light in vitiligo. Br J Dermatol. 2012;167:468–78.

    Article  PubMed  CAS  Google Scholar 

  44. Lee BW, Schwartz RA, Hercogová J, Valle Y, Lotti TM. Vitiligo road map. Dermatol Ther. 2012;25(Suppl 1):S44–56.

    Article  PubMed  Google Scholar 

  45. Bulat V, Situm M, Dediol I, Ljubicić I, Bradić L. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol. 2011;35(Suppl 2):147–51.

    PubMed  Google Scholar 

  46. Lee CH, Wu SB, Hong CH, Yu HS, Wei YH. Molecular mechanisms of UV-induced apoptosis and its effects on skin residential cells: the implication in UV-based phototherapy. Int J Mol Sci. 2013;14:6414–35.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  47. Korobko IV. Review of current clinical studies of vitiligo treatments. Dermatol Ther. 2012;25(Suppl 1):S17–27.

    Article  PubMed  Google Scholar 

  48. Itoi S, Tanemura A, Nishioka M, Sakimoto K, Iimuro E, Katayama I. Evaluation of the clinical safety and efficacy of a newly developed 308-nm excimer lamp for vitiligo vulgaris. J Dermatol. 2012;39:559–61.

    Article  PubMed  Google Scholar 

  49. Mehraban S, Feily A. 308 nm excimer laser in dermatology. J Lasers Med Sci. 2014;5:8–12.

    Google Scholar 

  50. Al-Shobaili HA. Treatment of vitiligo patients by excimer laser improves patients’ quality of life. J Cutan Med Surg. 2015;19:50–6.

    Article  PubMed  Google Scholar 

  51. Mouzakis JA, Liu S, Cohen G. Rapid response of facial vitiligo to 308nm excimer laser and topical calcipotriene. J Clin Aesthet Dermatol. 2011;4:41–4.

    PubMed  PubMed Central  Google Scholar 

  52. Welsh O, Herz-Ruelas ME, Gómez M, Ocampo-Candiani J. Therapeutic evaluation of UVB-targeted phototherapy in vitiligo that affects less than 10 % of the body surface area. Int J Dermatol. 2009;48:529–34. doi:10.1111/j.1365-4632.2009.03928.x.

    Article  PubMed  Google Scholar 

  53. Majid I. Efficacy of targeted narrowband ultraviolet B therapy in vitiligo. Indian J Dermatol. 2014;59:485–9.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Kaliyadan F, Ashique KT. Optimizing the efficacy of targeted phototherapy by marking early vitiligo lesions after visualizing under a Wood’s lamp. J Am Acad Dermatol. 2014;71:e69.

    Article  PubMed  Google Scholar 

  55. Lotti TM, Hercogová J, Schwartz RA, Tsampau D, Korobko I, Pietrzak A, et al. Treatments of vitiligo: what’s new at the horizon. Dermatol Ther. 2012;25(Suppl 1):S32–40.

    Article  PubMed  Google Scholar 

  56. Hamzavi IH, Lim HW, Syed ZU. Ultraviolet-based therapy for vitiligo: what’s new? Indian J Dermatol Venereol Leprol. 2012;78:42–8.

    Article  PubMed  Google Scholar 

  57. Lee KY, Jeon SY, Hong JW, Choi KW, Lee CY, Choi SJ, et al. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol. 2013;27:609–16.

    Article  PubMed  CAS  Google Scholar 

  58. Noborio R, Morita A. Preferential induction of endothelin-1 in a human epidermal equivalent model by narrow-band ultraviolet B light sources. Photodermatol Photoimmunol Photomed. 2010;26:159–61.

    Article  PubMed  CAS  Google Scholar 

  59. Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, et al. Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol. 2015;135:2068–76.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  60. Eby JM, Kang HK, Tully ST, Bindeman WE, Peiffer DS, Chatterjee S, et al. CCL22 to activate treg migration and suppress depigmentation in vitiligo. J Invest Dermatol. 2015;135:1574–80.

    Article  PubMed  CAS  Google Scholar 

  61. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011. http://handbook.cochrane.org. Accessed Oct 26 2015.

  62. Verhaeghe E, Lodewick E, van Geel N, Lambert J. Intrapatient comparison of 308-nm monochromatic excimer light and localized narrow-band UVB phototherapy in the treatment of vitiligo: a randomized controlled trial. Dermatology. 2011;223:343–8.

    Article  PubMed  CAS  Google Scholar 

  63. Casacci M, Thomas P, Pacifico A, Bonnevalle A, Paro Vidolin A, Leone G. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311–313 nm) in the treatment of vitiligo–a multicentre controlled study. J Eur Acad Dermatol Venereol. 2007;21:956–63.

    Article  PubMed  CAS  Google Scholar 

  64. Shi Q, Li K, Fu J, Wang Y, Ma C, Li Q, et al. Comparison of the 308-nm excimer laser with the 308-nm excimer lamp in the treatment of vitiligo–a randomized bilateral comparison study. Photodermatol Photoimmunol Photomed. 2013;29:27–33.

    Article  PubMed  Google Scholar 

  65. Le Duff F, Fontas E, Giacchero D, Sillard L, Lacour JP, Ortonne JP, et al. 308-nm excimer lamp vs. 308-nm excimer laser for treating vitiligo: a randomized study. Br J Dermatol. 2010;163:188–92.

    PubMed  Google Scholar 

  66. Yan Y, Li J, Wang R, Zhong RP, Guo LH, Zhu MH. A randomized comparative clinical trial of 308 monochromatic excimer light and 311 nm narrow-band ultraviolet in treating vitiligo [in Chinese]. J Clin Dermatol. 2013;2:120–3.

    Google Scholar 

  67. Liu YB, Yang YF, Song LX, Shan YH, Wang Y, Ma TQ, et al. Comparison of 308 nm excimer laser and 308 nm excimer lamp in treatment of vitiligo [in Chinese]. Clin Misdiagnosis Mistherapy. 2013;6:58–61.

    Google Scholar 

  68. Lan CC, Yu HS, Lu JH, Wu CS, Lai HC. Irradiance, but not fluence, plays a crucial role in UVB-induced immature pigment cell development: new insights for efficient UVB phototherapy. Pigment Cell Melanoma Res. 2013;26:367–76.

    Article  PubMed  CAS  Google Scholar 

  69. Sun Y, Wu Y, Xiao B, Li L, Chen HD, Gao XH. Treatment of 308-nm excimer laser on vitiligo: a systemic review of randomized controlled trials. J Dermatolog Treat. 2015;26:347–53.

    Article  PubMed  Google Scholar 

  70. Xiao BH, Wu Y, Sun Y, Chen HD, Gao XH. Treatment of vitiligo with NB-UVB: a systematic review. J Dermatolog Treat. 2015;26:340–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatology Department, Federal University of São Paulo (UNIFESP), São Paulo, Brazil

    Celso Lopes

  2. Division of Emergency Medicine and Evidence-Based Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil

    Virginia Fernandes Moça Trevisani

  3. Discipline of Rheumatology, Santo Amaro University (UNISA), São Paulo, Brazil

    Virginia Fernandes Moça Trevisani

  4. Internal Medicine and Evidence-Based Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil

    Tamara Melnik

  5. Brazilian Cochrane Center, São Paulo, Brazil

    Tamara Melnik

  6. Disciplina de Medicina Baseada em Evidência, Universidade Federal de São Paulo, Rua Botucatu, 740-3° andar-Vila Clementino, São Paulo, SP, 04023-900, Brazil

    Virginia Fernandes Moça Trevisani

Authors
  1. Celso Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Virginia Fernandes Moça Trevisani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tamara Melnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Virginia Fernandes Moça Trevisani.

Ethics declarations

Conflicts of interest

The authors, Celso Lopes, Virginia Fernandes Moça Trevisani, and Tamara Melnik, declare no conflicts of interest.

Funding sources

No funding was received.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1: Search method for identification of studies (PubMed) (PDF 78 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lopes, C., Trevisani, V.F.M. & Melnik, T. Efficacy and Safety of 308-nm Monochromatic Excimer Lamp Versus Other Phototherapy Devices for Vitiligo: A Systematic Review with Meta-Analysis. Am J Clin Dermatol 17, 23–32 (2016). https://doi.org/10.1007/s40257-015-0164-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-015-0164-2

Keywords

Search

Navigation